CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

drisapersen

Nucleic acidexperimental

Drisapersen is an experimental drug that was under development by BioMarin, after acquisition of Prosensa, for the treatment of Duchenne muscular dystrophy. — Wikipedia

Clinical trial activity

9 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
8
Phase 3
5
Phase 4
0

Earliest trial started Mar 1, 2008 (NCT01910649)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2010

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Dystrophin pre-mRNAANTISENSE INHIBITOR

    Dystrophin pre-mRNA antisense inhibitor

    Induces specific exon skipping during messenger RNA (mRNA) splicing correcting the open reading frame of the DMD gene and thus to restore dystrophin expression.

  • Dystrophin pre-mRNAOTHER

    Dystrophin pre-mRNA other

    Induces specific exon skipping during messenger RNA (mRNA) splicing correcting the open reading frame of the DMD gene and thus to restore dystrophin expression.

  • Dystrophin pre-mRNAPOSITIVE MODULATOR

    Dystrophin pre-mRNA positive modulator

    Induces specific exon skipping during messenger RNA (mRNA) splicing correcting the open reading frame of the DMD gene and thus to restore dystrophin expression.

  • DystrophinSupplementation

    DMD supplementation

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • drisapersen
  • drisapersen
  • drisapersen
  • drisapersen
  • gsk2402968
  • gsk2402968a
  • gsk2402968a
  • gsk2404968
  • gsk 2404968
  • h51aon23
  • h51aon23
  • pro051

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02636686Phase 3Dec 1, 2015Biomarin
NCT01890798Phase 3Jan 1, 2014GlaxoSmithKline
NCT01803412Phase 3May 1, 2013Biomarin
NCT01462292Phase 2Oct 1, 2011GlaxoSmithKline
NCT01480245Phase 3Sep 1, 2011GlaxoSmithKline
NCT01254019Phase 3Dec 1, 2010GlaxoSmithKline
NCT01153932Phase 2Sep 1, 2010GlaxoSmithKline
NCT01128855Phase 1Jul 1, 2010GlaxoSmithKline
NCT01910649Phase 2Mar 1, 2008Biomarin, Katholieke Universiteit Leuven
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit6632010
BiomarinFor profit3322008
Katholieke Universiteit LeuvenAcademic/Hospital1012008
3 organizations
Page 1 / 1